Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab
Thyroid dysfunction during Ate/Bev therapy is prognostically significant. NTIS reflects systemic deterioration and portends poor survival, whereas thyroid AEs may suggest favorable immune activation. Routine monitoring of thyroid function may aid in risk stratification.
Authors
- Chen-Chun Lin
- Chung-Wei Su
- Yi-Chung Hsieh
- Po-Ting Lin
- Chun-Yen Lin
- I.-Wen Chen
- Wei Teng
- Wei-Ting Chen
- Cheng-Wei Lin
- Tsung-Han Wu
- Shi-Ming Lin
Institutions
- Chang Gung University (TW)
- National Tsing Hua University (TW)
- Chang Gung Memorial Hospital (TW)
- Taipei Municipal YangMing Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2026-01-27
- DOI
- https://doi.org/10.1007/s00262-026-04308-z
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chang Gung Medical Foundation